Page last updated: 2024-11-06

ceftezole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ceftezole: RN given refers to (6R-(trans))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ceftezole : A first-generation cephalosporin antibiotic having (1,3,4-thiadiazol-2-ylsulfanyl)methyl and [2-(1H-tetrazol-1-yl)acetamido side groups located at positions 3 and 7 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65755
CHEMBL ID1697829
CHEBI ID135716
SCHEMBL ID147529
MeSH IDM0060092

Synonyms (47)

Synonym
(6r,7r)-8-oxo-7-[(1h-tetrazol-1-ylacetyl)amino]-3-[(1,3,4-thiadiazol-2-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ceftezole
26973-24-0
ceftezole (inn)
D07656
ctz ,
demethylcefazolin
ceftezol
CHEBI:135716
7-[2-(1h-tetrazol-1-yl)acetamido]-3-[(1,3,4-thiadiazol-2-ylsulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid
demethyl cefazolin
(6r,7r)-8-oxo-7-[2-(1h-tetrazol-1-yl)acetamido]-3-[(1,3,4-thiadiazol-2-ylsulfanyl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ceftezolum
(6r,7r)-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-3-(1,3,4-thiadiazol-2-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CHEMBL1697829
j01db12
(6r,7r)-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-3-(1,3,4-thiadiazol-2-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;ceftezole
A818761
unii-2z86syp11w
(6r,7r)-8-oxo-7-(2-(1h-tetrazol-1-yl)acetamido)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
ceftezol [inn-spanish]
2z86syp11w ,
ceftezolum [inn-latin]
ceftezole [inn]
cg-b 3 q
S5289
smr004701245
MLS006010107
SCHEMBL147529
ceftezole [who-dd]
ceftezole [mi]
C2770
DTXSID0022771
J-016638
(6r,7r)-8-oxo-7-[[1-oxo-2-(1-tetrazolyl)ethyl]amino]-3-[(1,3,4-thiadiazol-2-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-7-(2-(1h-tetrazol-1-yl)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Q5057295
HY-N7095
DB13821
mfcd00274176
AS-13011
BCP12070
gtpl12259
fr10123
CCG-269124
CS-0077833
AKOS037643294

Research Excerpts

Pharmacokinetics

The pharmacokinetic parameters of ceftezole were obtained by analyzing the serum level data of the drug using a one-compartment open model.

ExcerptReferenceRelevance
"The adult volunteers were given 1 g of ceftezole as a single intramuscular dose to investigate the pharmacokinetic profile of this new cephalosporin."( Pharmacokinetic studies on ceftezole.
De Pascale, A; Del Mastro, S; Fraschini, F; Scaglione, F, 1986
)
0.84
" The pharmacokinetic parameters of ceftezole were obtained by analyzing the serum level data of the drug using a one-compartment open model."( Pharmacokinetics of ceftezole in patients with normal and impaired renal function.
Kuroda, K; Ohkawa, M, 1980
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
thiadiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (76.47)18.7374
1990's1 (5.88)18.2507
2000's2 (11.76)29.6817
2010's0 (0.00)24.3611
2020's1 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.90 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other18 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]